In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Significant periods of weight regain were observed at eight, 12, and 20 weeks after stopping the anti-obesity medications. The analysis revealed that the weight rebound typically continued for an ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

The Financial Supervisory Service issued its latest consumer advisory pertaining to insurance claims for various forms of ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

According to a recent study, nearly three in four Americans are overweight. Worse, this report predicts that for decades to ...